Potential Synergistic Association of Donepezil and Metformin With COVID-19 Mortality in Dementia Patients
The Journal of Infectious Diseases · 2026-10-28
DOI: 10.1093/infdis/jiag528 ↗Abstract
Abstract Background Older adults with dementia face markedly elevated mortality from COVID-19. Both donepezil and metformin have anti-inflammatory effects and are associated with improved outcomes in respiratory viral infections, but whether their combined use is associated with lower COVID-19 mortality remains unknown. Methods We conducted a retrospective cohort study using the National Clinical Cohort Collaborative (N3C) data enclave, including adults aged ≥65 years with primary SARS-CoV-2 infection. We evaluated the association between donepezil monotherapy (5 mg or 10 mg) and COVID-19 mortality using 1-to-1 propensity score-matched analyses. Analyses were stratified by diabetes and metformin use. Results Among patients with dementia, 30-day mortality was lower in patients receiving donepezil 5 mg compared with matched untreated controls (10.3% vs 13.2%; P = .00046) and similarly for 10 mg (10.3% vs 13.4%; P = .0014). Among patients with dementia and diabetes, donepezil–metformin use was associated with the lowest mortality, approaching levels in matched individuals without dementia or diabetes. Metformin or donepezil alone was associated with modest reductions. Among donepezil users, those with diabetes treated with metformin had lower mortality than those without diabetes (30-day: 7.6% vs 10.2%, P = .016; significant only after FDR correction). No significant mortality differences by diabetes or metformin use were observed among dementia patients not receiving donepezil. Conclusions Donepezil use was associated with reduced COVID-19 mortality in older adults with dementia, with findings consistent with a potential synergistic association with metformin. These findings warrant further study of cholinergic modulation, alone or with metabolic therapies, to reduce severe COVID-19 outcomes.
EUVIMED